Rare Hematopoietic Stem Cell Disorder

Data confirm the safety and efficacy of ravulizumab among patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab, according to results of the REACTION study presented at ASH Annual Meeting and Exposition.